Table 1.

Results from the TruSight Myeloid Sequencing Panel for each participant at each time point evaluated after GT

Patient ID	Age at GT (mo)	Time point after GT (mo)	Variant detected (pos/neg)	Variant/description	VAF, %
401	184	0∗	Negative	—	—
		12	Negative	—	—
		48	Negative	—	—
		72	Negative	—	—
402†	4	0∗	Positive	KIT- VUS c.1700A>G (p.N567S)	50
		120	Positive	KIT- VUS c.1700A>G (p.N567S)	50
404†	3	0∗	Positive	KIT- VUS c.1700A>G (p.N567S)	49
		96	Positive	KIT- VUS c.1700A>G (p.N567S)	49
405	8	0∗	Negative	—	—
		48	Negative	—	—
		96	Negative	—	—
407	14	60	Negative	—	—
408	3	48	Negative	—	—
409	20	0∗	Negative	—	—
		84	Negative	—	—
410	3	36	Positive	TP53- LB c.1015G>A (p.E339K)	48
Controls ×5	N/A	N/A	Negative	—	—

LB, likely benign; VUS, variant of uncertain significance; N/A, not applicable.

^∗0, baseline sample before exposure to busulfan.

^†Sibling donor.